1. Analyzing Phenotypes Post-Exposure in Allergic Rhinitis (APPEAR) in the Environmental Exposure Unit (EEU).
- Author
-
Davis A, Linton S, Hossenbaccus L, Thiele J, Botting H, Walker T, Steacy LM, and Ellis AK
- Abstract
Background: Previous studies have defined clinical phenotypes of allergic rhinitis (AR) after allergen exposure using the time course of the total nasal symptom score (TNSS)., Objective: We aimed to validate previously proposed AR phenotypes across different allergens (birch, grass, ragweed, house dust mite) following exposure in the Environmental Exposure Unit (EEU)., Methods: The Analyzing Phenotypes Post-Exposure in Allergic Rhinitis (APPEAR) database comprises 153 participants from EEU studies conducted between 2010-2021 by Kingston Allergy Research. TNSS, nasal congestion symptom scores, and percent change in peak nasal inspiratory flow from baseline (%ΔPB) were recorded for each participant. Participants were phenotyped using previously described criteria RESULTS: 65 participants (42.5%) were classified as Early-phase Responders (EPR), 58 (37.9%) as Protracted Early-phase Responders (pEPR), 13 (8.5%) as Dual Responders (DR), and 17 (11.1%) as Low Responders (LoR). Significant negative correlations exist between TNSS and %ΔPB (r = -0.99, p<0.0001), and nasal congestion symptom score and %ΔPB (r = -0.99, p<0.0001). At the beginning of the late-phase AR response (6 to 7 hours), pEPRs had significantly higher TNSS compared to EPRs, DRs, and LoRs (p<0.0001). By the end of the study (up to 12 hours), DRs and pEPRs had significantly higher TNSS compared to EPRs and LoRs (p<0.0001). Visible and statistical validity between the phenotypes were also confirmed by assessing participants' mean TNSS and mean %ΔPB over time when grouping by phenotype., Conclusion: This study confirms distinct phenotypes exist in the late-phase AR response amongst different allergens and in a greater sample size than described previously, which could provide clinical benefit., Competing Interests: Declaration of competing interest Abigail Davis, Sophia Linton, Lubnaa Hossenbaccus, Jenny Thiele, Hannah Botting, Terry Walker, Lisa Steacy: None Anne K Ellis: In the past three years, Dr. Anne K. Ellis has participated in advisory boards for AstraZeneca, Abbvie Pharma, LEO Pharma, Miravo, Novartis, Sanofi, has been a speaker for ALK AbelloAstraZeneca, COVIS Pharma, GSK, Novartis Pharmaceuticals, Orexo, Regeneron Pharamaceuticals, and Sanofi-. Her institution has received research grants from ALK Abello, AstraZeneca, Bayer, Novartis Pharmaceuticals, Sanofi (and Opella Healthcare SAS), and Regeneron Pharmaceuticals. She has also served as an independent consultant to Bayer LLC, ARS, GSK, and Regeneron Pharmaceuticals., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF